Navigation Links
GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
Date:7/5/2011

RESEARCH TRIANGLE PARK, N.C., July 5, 2011 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today announced that it has implemented the next phase of its new incentive compensation program for professional sales representatives with the introduction of a new performance evaluation methodology and process.  

In January 2011, GSK eliminated individual sales goals as part of the company's incentive compensation program for sales professionals who work directly with healthcare professionals.  Beginning July 1, GSK is putting in place a new method for evaluating sales professionals' performance and bonus in alignment with the company's values of transparency, respect for people, integrity and focus on the patient.  

Under the new system, GSK's sales professionals who work directly with healthcare providers will continue to be compensated with a competitive mix of salary and bonus.  In place of individual sales targets, three primary factors will be evaluated to assess performance and determine bonuses: selling competency, customer evaluations, and the overall performance of their business unit.

"Our sales professionals play a critical role in providing doctors with appropriate, updated information on the safety and benefits of our medicines.  This information helps doctors make informed treatment decisions for their patients," said Deirdre Connelly, President, North America Pharmaceuticals, GlaxoSmithKline. "This industry-leading incentive program aligns our performance measures and rewards with our values so doctors can be confident that our sales professionals are focused on improving patient health."

Since first announcing its plans in July 2010 to radically change its sales incentive compensation system, GSK has conducted extensive research to define how best to obtain robust, ongoing, unbiased assessments of the effectiveness of its sales professionals in meeting customer needs. This effort is part of a wider evolution to align the company's sales and marketing programs with societal and customer expectations.

"Along with changing many aspects of how we conduct our business, we have also invested heavily in training and compliance programs to ensure that we are operating at or above the pharmaceutical industry code of ethics," Connelly said.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information go to us.gsk.com, follow us on twitter.com/GSKUS or visit our blog (www.morethanmedicine.us.gsk.com/blog/).

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2010.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
11. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... May 9, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, today announced it has earned a spot on ... list. The Company was ranked among 500 U.S. employers ... and Healthcare Equipment and Services. The annual ... an anonymous, independent survey of over 30,000 employees across ...
Breaking Medicine Technology:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... for Global Policy Solutions is vehemently opposed to Donald Trump’s budget, “A New ... for despair that inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... tract in which the endometrial lining of the uterus spreads into the ... Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding may ...
(Date:5/24/2017)... ... ... thinking of a visit to San Francisco , fall is a great time to ... , Business Architecture Associates is pleased to offer 5 days of training courses, available to ... for individuals, and as 4-½ day corporate package for up to 3 employees with the ...
(Date:5/24/2017)... ... May 24, 2017 , ... The ... nonprofit hospitals and health systems in the nation and help their organizations navigate ... professional organizations and been instrumental in developing successful hospital and health system strategy. ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... (PVDF) based sleep diagnostics sensors, announced today it had completed the first phase ... a mix of domestic and rest of world (ROW) authorized dealers specializing in ...
Breaking Medicine News(10 mins):